154 related articles for article (PubMed ID: 15377852)
41. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
42. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindström L; Bergh J
Breast Cancer Res Treat; 2011 Jan; 125(2):553-61. PubMed ID: 20628810
[TBL] [Abstract][Full Text] [Related]
43. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
44. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.
Gebauer G; Fehm T; Merkle E; Jaeger W; Mitze M
Anticancer Res; 2003; 23(5b):4319-24. PubMed ID: 14666645
[TBL] [Abstract][Full Text] [Related]
45. Positive bone marrow biopsy is associated with a decreased disease-free survival in patients with operable breast cancer.
Fortunato L; Mascaro A; Baldi A; Farina M; Cortese G; Ventrone MA; Amini M; Vitelli C
Ann Surg Oncol; 2009 Nov; 16(11):3010-9. PubMed ID: 19641970
[TBL] [Abstract][Full Text] [Related]
46. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.
Tapia C; Schraml P; Simon R; Al-Kuraya KS; Maurer R; Mirlacher M; Novotny H; Spichtin H; Mihatsch MJ; Sauter G
Int J Oncol; 2004 Dec; 25(6):1551-7. PubMed ID: 15547690
[TBL] [Abstract][Full Text] [Related]
47. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
48. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
49. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
50. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
51. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
52. Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy.
Bechmann T; Olsen DA; Jakobsen EH; Madsen JS; Brandslund I; Jylling AM; Steffensen KD; Jakobsen A
Oncol Rep; 2013 Apr; 29(4):1475-82. PubMed ID: 23417164
[TBL] [Abstract][Full Text] [Related]
53. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.
Naume B; Borgen E; Kvalheim G; Kåresen R; Qvist H; Sauer T; Kumar T; Nesland JM
Clin Cancer Res; 2001 Dec; 7(12):4122-9. PubMed ID: 11751511
[TBL] [Abstract][Full Text] [Related]
54. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
[TBL] [Abstract][Full Text] [Related]
55. Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ.
Banys M; Hahn M; Gruber I; Krawczyk N; Wallwiener M; Hartkopf A; Taran FA; Röhm C; Kurth R; Becker S; Solomayer EF; Wallwiener D; Staebler A; Fehm T
Breast Cancer Res Treat; 2014 Apr; 144(3):531-8. PubMed ID: 24590774
[TBL] [Abstract][Full Text] [Related]
56. Prognostic relevance of the AQP5 -1364C>A polymorphism in primary breast cancer.
Kasimir-Bauer S; Heubner M; Otterbach F; Kimmig R; Siffert W; Adamzik M
Mol Med Rep; 2009; 2(4):645-50. PubMed ID: 21475880
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study.
Valladares-Ayerbes M; Iglesias-Díaz P; Díaz-Prado S; Ayude D; Medina V; Haz M; Reboredo M; Antolín S; Calvo L; Antón-Aparicio LM
J Cancer Res Clin Oncol; 2009 Sep; 135(9):1185-95. PubMed ID: 19221791
[TBL] [Abstract][Full Text] [Related]
58. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival.
López-Guerrero JA; Llombart-Cussac A; Noguera R; Navarro S; Pellin A; Almenar S; Vazquez-Alvadalejo C; Llombart-Bosch A
Int J Cancer; 2006 Apr; 118(7):1743-9. PubMed ID: 16217770
[TBL] [Abstract][Full Text] [Related]
59. DTCs in breast cancer: clinical research and practice.
Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
[TBL] [Abstract][Full Text] [Related]
60. Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Rack B; Zombirt E; Trapp E; Jückstock J; Andergassen U; Neugebauer J; Kost B; Weissenbacher T; Jeschke U; Schindlbeck C; Janni W; Alunni-Fabbroni M
Oncology; 2016; 90(4):232-8. PubMed ID: 26937631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
